| 產(chǎn)品編號(hào) | bs-6610R-PE-Cy5.5 |
| 英文名稱(chēng)1 | Rabbit Anti-BCAS2/PE-Cy5.5 Conjugated antibody |
| 中文名稱(chēng) | PE-Cy5.5標(biāo)記的乳腺癌相關(guān)蛋白2抗體 |
| 別 名 | DNA amplified in mammary carcinoma 1 protein; Spliceosome associated protein SPF 27; bcas2; Breast carcinoma amplified sequence 2; Breast carcinoma-amplified sequence 2; DAM1; MGC7712; Pre mRNA splicing factor SPF27; Pre-mRNA-splicing factor spf27; SPF27_HUMAN; Spliceosome associated protein amplified in breast cancer; Spliceosome-associated protein SPF 27. |
| 規(guī)格價(jià)格 | 100ul/2980元 購(gòu)買(mǎi) 大包裝/詢價(jià) |
| 說(shuō) 明 書(shū) | 100ul |
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 腫瘤細(xì)胞生物標(biāo)志物 表觀遺傳學(xué) |
| 抗體來(lái)源 | Rabbit |
| 克隆類(lèi)型 | Polyclonal |
| 交叉反應(yīng) | (predicted: Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse, Sheep, ) |
| 產(chǎn)品應(yīng)用 | IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 26kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human BCAS2 (162-210aa) |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲(chǔ) 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: BCAS2 is a ubiquitously expressed nuclear protein that was originally identified as being overexpressed in various breast cancer cell lines. BCAS2 is now known to be a component of the spliceosome, participating in the removal of introns from mRNA precursors. BCAS2 specifically interacts (in a ligand-independent manner) with thyroid hormone receptor beta, ER alpha (estrogen receptor alpha), PR (progesterone receptor), and PPAR gamma (Peroxisome proliferator-activated receptor gamma). BCAS2 functions as an ER coactivator and is capable of enhancing ER-mediated transcription. This suggests that BCAS2 is involved in the development of breast cancer. Function: Component of the PRP19-CDC5L complex that forms an integral part of the spliceosome and is required for activating pre-mRNA splicing. May have a scaffolding role in the spliceosome assembly as it contacts all other components of the core complex. Subunit: Component of the PRP19-CDC5L splicing complex composed of a core complex comprising a homotetramer of PRPF19, CDC5L, PLRG1 and BCAS2, and at least three less stably associated proteins CTNNBL1, CWC15 and HSPA8. Interacts directly in the complex with PRPF19, CDC5L and PLRG1. Subcellular Location: Nucleus, nucleolus. Tissue Specificity: Ubiquitously expressed. Similarity: Belongs to the SPF27 family. Database links: UniProtKB/Swiss-Prot: O75934.1 Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
